Physician profile
John M Zeroogian
NPI 1437149226
$15,624.94
in general payments reported to CMS, 2019-2025
36 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $1,575 · 2021: $3,385 · 2022: $3,771 · 2023: $2,345 · 2024: $2,642 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,915 · Education: $46.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,914.72 |
| Education | $46.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,823.64 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,920.01 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,277.82 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,037.37 | 2019-2024 | Entyvio |
| Redhill Biopharma INC. | $510.29 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Phathom Pharmaceuticals, INC. | $509.17 | 2023-2025 | Voquezna |
| Pfizer INC. | $488.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $472.50 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $437.49 | 2021-2024 | Dificid |
| Qol Medical, LLC | $428.05 | 2020-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $333.18 | 2020-2022 | |
| Gilead Sciences, INC. | $304.54 | 2021-2025 | |
| Celgene Corporation | $247.82 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $195.53 | 2022-2023 | Ibsrela |
| Celltrion USA INC. | $174.99 | 2024 | Vegzelma, Zymfentra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $168.88 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $165.28 | 2020-2021 | |
| Apollo Endosurgery US INC | $139.18 | 2023 | Overstitch Endoscopic Suturing System |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Boston Scientific Corporation | $91.31 | 2019 | |
| Fresenius Kabi USA, LLC | $90.16 | 2023 | Idacio |
| Lilly USA, LLC | $75.59 | 2024-2025 | Omvoh |
| Amgen INC. | $71.57 | 2019 | |
| Nestle Healthcare Nutrition INC. | $70.44 | 2021 | |
| Lucid Diagnostics INC. | $69.68 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $66.69 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $61.38 | 2024 | |
| Alfasigma USA, INC. | $47.56 | 2020-2021 | |
| Braintree Laboratories, INC. | $45.52 | 2021-2023 | Sutab |
| Ferring Pharmaceuticals INC. | $32.49 | 2019-2023 | Rebyota |
| Organon LLC | $31.90 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.58 | 2023 | Cyltezo |
| Medtronic, INC. | $25.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.38 | 2019 | |
| Evoke Pharma, INC. | $21.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zeroogian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.